Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 5;60(7):1100.
doi: 10.3390/medicina60071100.

Sporadic Parathyroid Adenoma: A Pilot Study of Novel Biomarkers in Females

Affiliations

Sporadic Parathyroid Adenoma: A Pilot Study of Novel Biomarkers in Females

Angeliki Cheva et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Parathyroid adenoma is a distinct cause of primary hyperparathyroidism, with the vast majority being sporadic ones. Proteomic analysis of parathyroid adenomas has proposed a large number of related proteins. The aim of this study is to evaluate the immunohistochemical staining of ANXA2, MED12, MAPK1 and VDR in parathyroid adenoma tissue. Materials and Methods: Fifty-one parathyroid adenomas were analyzed for ANXA2, MED12, MAPK1 and VDR expressions. Tissue was extracted from formalin-fixed paraffin-embedded parathyroid adenoma specimens; an immunohistochemical study was applied, and the percentage of allocation and intensity were evaluated. Results: ANXA2 stained positively in 60.8% of all cell types, while MED12 had positive staining in 66%. MAPK1 expression was found to be negative in total, although a specific pattern for oxyphil cells was observed, as they stained positive in 17.7%. Finally, VDR staining was positive at 22.8%, based on nuclear staining. Conclusions: These immunohistochemical results could be utilized as biomarkers for the diagnosis of sporadic parathyroid adenoma. It is of great importance that a distinct immunophenotype of nodule-forming cells in a positive adenoma could suggest a specific pattern of adenoma development, as in hereditary patterns.

Keywords: ANXA2; MAPK1; MED12; VDR; immunohistochemistry; parathyroid adenoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
ANXA2 immunohistochemical staining: (a) negative staining of chief cells and positive staining of normal parathyroid tissue; (b) positive staining of chief cells; (c) positive staining of clear cells; (d) a distinct immunophenotype of chief cell nodule in an adenoma.
Figure 2
Figure 2
MED12 immunohistochemical staining: (a) positivity in normal parathyroid tissue, (b) a distinct immunophenotype of oxyphil cell nodule in a positive chief cell adenoma; (c) positive chief cells (blue arrow), clear cells (red arrow) and oxyphil cells (green arrow).
Figure 3
Figure 3
MAPK1 immunohistochemical staining: (a) positive oxyphil cells and negative chief cells; (b) negative chief cells.
Figure 4
Figure 4
VDR immunohistochemical staining: (a) positive nuclear staining in chief (green arrow) and clear (red arrow) cells; (b) negative (blue) and positive (brown) nuclear staining in chief cells.
Figure 5
Figure 5
VDR immunohistochemical staining: (a) positive membranous staining in the apical side of chief cells; (b) positive, intense cytoplasmic staining in group of chief cells (green circle) encircled by positive moderate cytoplasmic staining; (c) a distinct immunophenotype of chief cell nodule with mild intensity in an intense positive chief cell adenoma; (d) intense positive membranous staining in group of chief cells (red circle) encircled by mild positive membranous staining chief cells.

References

    1. Bilezikian J.P., Brandi M.L., Eastell R., Silverberg S.J., Udelsman R., Marcocci C., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 2014;99:3561–3569. doi: 10.1210/jc.2014-1413. - DOI - PMC - PubMed
    1. Cusano N.E., Cetani F. Normocalcemic primary hyperparathyroidism. Arch. Endocrinol. Metab. 2022;66:666–677. doi: 10.20945/2359-3997000000556. - DOI - PMC - PubMed
    1. Zavatta G., Clarke B.L. Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed? JBMR Plus. 2020;4:e10391. doi: 10.1002/jbm4.10391. - DOI - PMC - PubMed
    1. Erickson L.A., Mete O., Juhlin C.C., Perren A., Gill A.J. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr. Pathol. 2022;33:64–89. doi: 10.1007/s12022-022-09709-1. - DOI - PubMed
    1. Cetani F., Pardi E., Borsari S., Marcocci C. Molecular pathogenesis of primary hyperparathyroidism. J. Endocrinol. Invest. 2011;34:35–39. - PubMed

LinkOut - more resources